Search for better anti-leishmanial drugs is still imperative, since the
current treatment with antimonials is toxic, expensive, and requires
prolonged intramuscular administration (EM Netto et al. 1990
Transactions 84: 367). All these features are serious obstacles to
compliance in endemically exposed populations.
